Pakistan Call For Cheaper TB Drugs
Haseeb Ahmed Khan, chairman of the Pakistan Pharmaceutical ManufacturersAssociation, has proposed to the government that the Association could form a group of pharmaceutical concerns to produce antituberculosis drugs on a mass scale to meet local demand at reduced cost to users.
Mr Haseeb said in an interview to support his proposal that "besides anti-TB medicines, all essential drugs could be produced on a mass scale and made available at an economical price."
Commenting on the incidence of TB in Pakistan, Ghazala Ansari, director of the Ojha Institute of Chest Diseases, said "about 250 persons were infected per 100,000 of the population, which was the highest in this part of the world."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze